Moxibustion for Fetus in Breech Presentation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00890474|
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : April 29, 2009
Objective: To evaluate moxibustion of the BL67 acupoint between 34 and 38 weeks of gestation to facilitate cephalic version of breech presentation in a Western setting. The hypothesis is that moxibustion increase the likelihood of cephalic version.
Design: Randomised controlled trial Setting: University hospital. Population: A total of 212 consenting women between 34 and 36 weeks of gestation with a single fetus in breech presentation will be randomised to moxibustion (n=106) or expectant management (n=106).
Main Outcome Measure: Cephalic presentation at delivery or before external cephalic version.
|Condition or disease||Intervention/treatment||Phase|
|Breech Presentation||Procedure: Moxibustion of the BL67 acupoint||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||212 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||Moxibustion for Fetus in Breech Presentation|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||January 2009|
Procedure: Moxibustion of the BL67 acupoint
Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
|No Intervention: Control|
- Cephalic presentation at delivery or before external cephalic version [ Time Frame: end of pregnancy ]
- Mode of delivery [ Time Frame: end of pregnancy ]
- Women's views on the intervention [ Time Frame: end of pregnancy ]
- External cephalic version [ Time Frame: end of pregnancy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00890474
|Hôpitaux Universitaires de Genève|